Lexington, MA – January 9, 2026 – Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced new data from a post hoc analysis of the eNRGy trial (NCT02912949), evaluating zenocutuzumab in patients with advanced neuregulin 1 fusion-positive (NRG1+) pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) who continued therapy beyond progression. Results were presented in a poster session at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, California.

“These findings highlight an important therapeutic opportunity for patients with NRG1 ...

• IMREPLYS^® is the first treatment for H-ARS approved in Europe
• Approval based upon IMREPLYS^® significantly improving survival, accelerating recovery of white blood cells and platelets, and reducing rates of infection and sepsis after radiation exposure without the need for supportive care such as blood products.²

Lexington, MA – September 9, 2025 – Partner Therapeutics, Inc. (PTx) today announced that the European Commission has granted a marketing authorization in the European Union (EU) for IMREPLYS^® (sargramostim, rhu GM-CSF), the ...

Lexington, MA – June 20, 2025 – Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of PTx’s Marketing Authorisation Application (MAA) for IMREPLYS® (sargramostim, rhu GM-CSF), the same formulation that was approved by the U.S. Food and Drug Administration (FDA) under the brand name LEUKINE® in 2018. IMPREPLYS would be indicated for treatment of patients of all ages acutely exposed to myelosuppressive ...